<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175925</url>
  </required_header>
  <id_info>
    <org_study_id>IM032-007</org_study_id>
    <nct_id>NCT04175925</nct_id>
  </id_info>
  <brief_title>A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986322 in Healthy Participants Including an Open-label Assessment of Food and pH Effects on Relative Bioavailability of BMS-986322</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study assessing the drug levels and drug effects of variable doses of BMS-986322 in Healthy
      Participants compared to a placebo. The study also assesses how BMS-986322 affects the body
      with food and its acidity levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruitment temporarily on hold due to COVID-19.

      This is a randomized, double-blind, placebo-controlled study which will investigate the
      safety, tolerability, and PK of single and multiple oral doses of BMS-986322 in healthy
      subjects. The trial consists of three parts: Part A - a single ascending dose (SAD) safety
      and pharmacokinetic (PK) evaluation; Part B -a multiple ascending dose (MAD) safety, PK, and
      pharmacodynamic (PD) evaluation; and Part C - effect of food and pH on PK and safety.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 14, 2019</start_date>
  <completion_date type="Anticipated">October 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 23, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Death</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Effects (AEs)</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events leading to discontinuation</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs of body temperature</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs of blood pressure</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs of respiratory rate</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with abnormal physical examinations</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in Electrocardiograms (ECGs)</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in lab assessment of blood serum</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically significant changes in lab assessment of urine</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Clinically significant changes in lab assessment of blood</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) of BMS-986322 in Part C</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum concentration (Tmax) of BMS-986322 in Part C</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination rate constant (Lambda_z) of BMS-986322 in Part C</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (T-Half) of BMS-986322 in Part C</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve extrapolated to infinity [AUC(INF)] of BMS-986322 in Part C</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration [AUC(0-T)] of BMS-986322 in Part C</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent oral clearance (CL/F) of BMS-986322 in Part C</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distrubution at terminal phase (Vz/F) of BMS-986322 in Part C</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">432</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Part A: BMS-986322</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: BMS-986322 Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: BMS-986322 with famotidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986322</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Part A: BMS-986322</arm_group_label>
    <arm_group_label>Part B: BMS-986322 Placebo</arm_group_label>
    <arm_group_label>Part C: BMS-986322 with famotidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BMS-986322 Placebo</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Part A: BMS-986322</arm_group_label>
    <arm_group_label>Part B: BMS-986322 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>famotidine</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Part C: BMS-986322 with famotidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy Participant, as determined by no clinically significant deviation from normal
             in medical history, physical examination, ECGs, and clinical laboratory determinations

          -  Body mass index (BMI) of 18.0 kg/m^2 to 32.0 kg/m^2, inclusive, and body weight â‰¥ 50
             kg, at screening

          -  Women and men must agree to follow methods of contraception.

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  History of recent infection

          -  History of allergy to BMS-986322 or other compounds

        Other protocol-defined inclusion/exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences - Lenexa</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

